Objective: To determine whether subclinical hypothyroidism (SCH) causes decrements in health status, mood, and/or cognitive function.
Results: Mean TSH levels increased to 17 mU/L on the SCH arm (P <0.0001). Mean free T4 and free T3 levels remained within the normal range. The Profile of Mood States fatigue subscale and Short Form 36 general health subscale were slightly worse during the SCH arm. Measures of working memory (N-back, subject ordered pointing) were worse during the SCH arm. These differences did not depend on mood or health status but were related to changes in free T 4 or free T 3 levels. There were no decrements in declarative memory or motor learning.
Conclusions:
The authors found mild decrements in health status and mood in l-T4 treated hypothyroid patients when SCH was induced in a blinded, randomized fashion. More importantly, there were independent decrements in working memory, which suggests that SCH specifically impacts brain areas responsible for working memory.
COMMENT
The literature on cognitive function in patients with subclinical hypothyroidism (SCH) remains largely inconclusive. In 2004, a panel of experts reviewed the available literature and came to the conclusion that "there were insufficient data on the association between SCH and cognition defects" and, therefore, recommended "against treating such patients based on neuro-cognitive effects" (see Surks et al, JAMA 2004 ). The present study had the best possible methodological design. It included 19 women with known hypothyroidism, aged 20-75 years, all under stable l-T4 treatment for the previous 3 months and with normal thyroid function tests: mean of free T 4 1.32 ng/dl; free T 3 237 pg/dl; TSH 3.53 mU/L. The experimental protocol was prospective, double-blinded, randomized, with a crossover trial between the 'normal' and 'reduced' l-T4 treatment periods in each patient. The SCH arm of the study was performed by calculating, for each patient, the decrement in l-T4 dosage needed to induce an elevation in serum TSH from the normal level to 10-20 mU/L, without inducing overt hypothyroidism (I wonder how the investigators did this!). This was indeed achieved by the investigators since, in the SCH phase, the patients had an increase in serum TSH reaching a mean of 17.4 mU/L, with a significant reduction in free T 4 (1.43 0.99 ng/dl; P<0.0001) and free T 3 (259 231 pg/dl; P=0.06), hence with free hormone levels still within the normal range. It should be noted, however, that the patients had better thyroid function tests during the 'euthyroid' phase than at baseline, and this was attributed by the authors to an improved therapeutic compliance during the study period. On the SCH arm of the study, the main results were to show a slight effect on general health and fatigue, and a more significant worsening of the working memory. Despite the admitted limitations of the study, accepted and discussed by the investigators, the present results are interesting as they tend to confirm the subjective impression of many clinicians dealing with such patients routinely. It is also worth mentioning that another recent study (see Razvi et al. in JCEM 92:1715 , 2007 ) also showed beneficial effects of Lthyroxine (compared to placebo) administration in patients with SCH. 
